Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Summary
This study includes Part A and Part B. Part A is a dose-finding study for subjects with chronic liver disease-related thrombocytopenia scheduled for elective surgery. Part B is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study designed to evaluate the efficacy and safety of Herombopag compared to placebo in patients with chronic liver disease-related thrombocytopenia undergoing elective invasive surgery.
Official title: The Efficacy and Safety of Herombopag in Treating Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery - A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
101
Start Date
2024-07-31
Completion Date
2025-12
Last Updated
2025-11-18
Healthy Volunteers
No
Interventions
Herombopag tablets
Herombopag tablets; dose 1 or dose 2, for 5 days
Herombopag placebo tablets
Herombopag placebo tablets; dose 1 or dose 2, for 5 days
Locations (1)
Zhongshan Hospital, affiliated with Fudan University
Shanghai, Shanghai Municipality, China